I think we'll get started. Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno ...

Thank you very much for joining us for the next session at the Leerink Global Healthcare Conference. I'm Marc Goodman, one of the biopharma analyst, and we're lucky to have Biogen with us here ...

On Tuesday, 11 March 2025, Premier Inc (NASDAQ: PINC) participated in Leerink’s Global Healthcare Conference 2025, discussing its strategic initiatives amidst a challenging healthcare environment.

will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40 am ET. A live webcast will be available on the Alumis website in the ...

In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price target of $5.00. The company’s shares opened today at ...

Leerink analyst Faisal Khurshid raised the firm’s price target on Trevi Therapeutics (TRVI) to $11 from $7 and keeps an Outperform rating on the shares. The firm views data from the RIVER study ...

Mark Grasso, Chief Financial Officer, Elektor: Good morning, everyone. And thanks to Mark and the Leerink team for having us today. I’m Mark Grasso. I’m the chief financial officer at Elektor ...

today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami. A live webcast of the presentation will be ...

For more detailed insights, please refer to the full transcript below. Dave Reisinger, Cover Diversified Biopharmaceuticals, Leerink Partners: All righty. Great. Well, welcome, everyone. My name is ...

On Tuesday, 11 March 2025, Revvity Inc. (NYSE: RVTY) presented at the Leerink Global Healthcare Conference 2025, outlining its strategic resilience amidst current economic challenges. The company ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...